Submitted to: Meeting Abstract
Publication Type: Abstract Only
Publication Acceptance Date: 4/22/2016
Publication Date: 7/23/2016
Citation: Casas, E., Cai, G., Kuehn, L.A., Register, K.B., Neill, J.D., McDaneld, T.G. 2016. Association of bta-miR-24-3p with serum antibody response to Mycoplasma spp. in beef cattle. 35th International Society for Animal Genetics Conference, July 23-27, 2016, Salt Lake City, Utah. p. 39.
Technical Abstract: The objective of this study was to identify microRNAs associated with a serum antibody response to Mycoplasma spp. in beef cattle. Serum from sixteen beef calves was collected at three points: summer of 2013, after calves were born; fall of the same year at weaning; and spring, 2014. All sera collected in summer were negative for IgG reactive with Mycoplasma spp. By the fall, eight animals were seropositive (positive group), while eight remained negative (negative group). By spring, all animals in both groups were seropositive. MicroRNAs were extracted and sequenced on the Illumina HiSeq next-generation sequencer. A total of 967,152 normalized sequences were identified as bta-miR-24-3p. There was a significant interaction between groups and season (P= 0.0268). During summer both groups had similar number of sequences for the bta-miR-24-3p (P=0.773). In the fall, the positive group had an increased number of sequences when compared with animals in the negative group (P= 0.021). The difference in the number of sequences for the bta-miR-24-3p increased in the positive group, when compared to the negative group during the following spring (P= 0.0001). Differential expression of miR-24-3p has been observed in human liver cell lines infected with hepatitis B virus. Production of bta-miR-24-3p may be associated with a host defense mechanism triggered by infection, or it may provide some advantage to a pathogen during infection of a host. Further studies are needed to establish if bta-miR-24-3p could be used as a diagnostic indicator of exposure, or whether intervention strategies could be developed to be used as an alternative to antibiotics for controlling disease due to Mycoplasma spp.